Pretax income is the income that a company earns before paying income taxes. Insulet's pretax income for the
three
months ended in Dec. 2023 was $108 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $215 Mil.
Insulet's pretax margin was 21.15%.
During the past 13 years, Insulet's highest Pretax Margin was 12.65%. The lowest was -23.26%. And the median was 0.84%.
Insulet Pre-Tax Income Historical Data
The historical data trend for Insulet's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Insulet's Pre-Tax Income
For the Medical Devices subindustry, Insulet's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insulet's Pre-Tax Income Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Insulet's Pre-Tax Income falls into.
Insulet Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Insulet's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $215 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insulet (NAS:PODD) Pre-Tax Income Explanation
Insulet's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 13 years, Insulet's highest Pretax Margin was 12.65%. The lowest was -23.26%. And the median was 0.84%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insulet Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Insulet's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PODD has been successfully added to your 